FPR2 is a therapeutic target in lung cancer

肺癌仍然是癌症相关死亡的最大原因，而长期吸烟是主要的危险因素。我们最近证明，一种名为SAA的蛋白质通过激活一种名为FPR2的受体，有助于慢性吸烟者发生肺气肿的破坏性炎症。我们将确定靶向FPR2受体的被称为促溶解介质的天然衍生产品是否将被证明是一种新的有效的肺癌治疗方法。

Lung cancer remains the biggest cause of cancer related deaths and chronic smoking is the major risk factor. We have recently demonstrated that a protein termed SAA contributes to damaging inflammation in chronic smokers that develop emphysema through activation of a receptor called FPR2. We will determine whether naturally derived products termed pro-resolving mediators that target this same FPR2 receptor will prove to be a novel and effective treatment for lung cancer.